Remove business
article thumbnail

STAT+: Can gene therapies make for a profitable business? Keep your eye on Bluebird Bio

STAT

Bluebird and the case for gene therapy profits Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? It’s a pure-play commercial gene therapy business. Continue to STAT+ to read the full story…

289
289
article thumbnail

STAT+: Akili abandons prescription business model, to lay off 40% of workers

STAT

Akili Interactive, which in 2020 made waves by receiving Food and Drug Administration clearance for its video game that improves symptoms of ADHD in children, on Wednesday announced it would reorient its business around selling its products directly to users over the counter, rather than by prescription.

Labelling 325
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Teladoc stock slides despite business growth, Medtronic CEO talks innovation

STAT

  Teladoc’s stock slides despite business growth Teladoc   Health  on Tuesday  reported  solid third quarter earnings showing $660 million in revenue for 8% year-over-year growth and improvement across business lines including BetterHelp and its closely watched chronic care segment.

223
223
article thumbnail

Mental health crisis centers and EmPATH units: offering care that busy ERs can’t

STAT

On a spring afternoon in Tucson, Ariz., about a half dozen children and teens hung out in the sunny common room of Pima County’s Crisis Response Center. Beyond the pastel-painted room stretched a long, wide hall where partitions separated individual beds, many left unmade with rumpled sheets.

361
361
article thumbnail

STAT+: Ketamine clinics’ bust serves as warning of business challenge facing psychedelic therapy

STAT

A chain of luxury ketamine clinics called Field Trip started churning through business strategies at an increasingly rapid pace late last year. went out of business. To both company insiders and those watching from the outside, the bubble was primed to burst by business leaders who were over-eager to grow.

242
242
article thumbnail

STAT+: EQRx abandons business plan around drug pricing, cuts jobs and programs

STAT

The company’s original business plan was to create new medicines in the same categories as high-priced cancer and specialty drugs and to sell them at lower prices through a “global buyers club” that included insurers and hospitals.

article thumbnail

Prabhat Balyan, Business Development Manager, AMI Polymer

Express Pharma

In this video: Prabhat Balyan, Business Development Manager, Ami Polymer Topic: Polymeric solutions for pharmaceutical industry Key Takeaway: Ami Polymer has a range of tubing solutions that serves the pharma industry The post Prabhat Balyan, Business Development Manager, AMI Polymer appeared first on Express Pharma.

87